key: cord-0951991-a0y1260g authors: Bagno, F. F.; Sergio, S. A. R.; Figueiredo, M. M.; Godoi, L. C.; Andrade, L. A. F.; Salazar, N. C.; Soares, C. P.; Aguiar, A.; Almeida, F. J.; da Silva, E. D.; Ferreira, A. G. P.; Durigon, E. L.; Gazzinelli, R. T.; Teixeira, S. M. R.; Fernandes, A. P. S. M.; da Fonseca, F. G. title: DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19 date: 2021-06-29 journal: nan DOI: 10.1101/2021.06.23.21259392 sha: ce5095240b4d1ee4c1ea93fea65caa014c50f320 doc_id: 951991 cord_uid: a0y1260g There is a massive demand to identify alternative methods to detect new cases of COVID-19 as well as to investigate the epidemiology of the disease. In many countries, importation of commercial kits poses a significant impact on their testing capacity and increases the costs for the public health system. We have developed an ELISA to detect IgG antibodies against SARS-CoV-2 using a recombinant viral nucleocapsid (rN) protein expressed in E. coli. Using a total of 894 clinical samples we showed that the rN-ELISA was able to detect IgG antibodies against SARS-CoV-2 with high sen-sitivity (97.5%) and specificity (96.3%) when compared to a commercial antibody test. After three external validation studies, we showed that the test accuracy was higher than 90%. The rN-ELISA IgG kit constitutes a convenient and specific method for the large-scale determination of SARS-Cov-2 antibodies in human sera with high reliability. SARS-CoV-2, a member of the Coronaviridae family, Betacoronavirus genus, is the causative agent of COVID-19, a disease marked by the occurrence of severe acute respiratory syndrome in many of the infected patients. The virus was first isolated on December, 2019, in Wuhan, China. Since then, it has spread quickly, and, by March 11, 2020 , the World Health Organization (WHO) declared COVID-19 pandemic. As of June 2021, the disease is close to reach the astonishing mark of 170 million people affected worldwide and has caused more than 3.7 million deaths [1] . Emergency of virus variants has brought more complexity to this scenario, since they may have been associated to overwhelmingly new outbreaks in large cities such as Manaus, Brazil [2] . Although the combination of PCR and serological tests such as enzyme-linked immunosorbent assays (ELISA) are ideal for an accurate diagnosis, the detection of antibodies is particularly relevant during later stages of infection [3] . Taking into account the rate of asymptomatic infections and the extent of the disease . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. transmission, serologic assays are needed for epidemiologic studies and surveillance. Also, serological tests may identify individuals who have developed immunity after the disease and are highly relevant as an assessment tool after vaccination [4] [5] [6] . SARS-CoV-2 has four structural proteins: Spike (S,) Envelope (E), Membrane (M), and Nucleocapsid (N). The S protein, which is cleaved into S1 (containing the receptor binding domain, RBD) and S2 (further cleaved into S2' to form the viral fusion peptide) subunits is critical for viral entry and has been described as a neutralizing target [7, 8] . Besides the S protein, the SARS-CoV-2 N protein has been described as an immunodominant antigen in studies with COVID-19 patients. Similar to SARS-CoV-1 (the causative agent of the 2003 SARS) N protein, this antigen is highly expressed during infection [9] [10] [11] , making it a suitable antigen to be included in serology-based diagnostics [13] [14] [15] . Due to the urgency and high demand, many serological tests to diagnose COVID-19 have been rapidly developed-and made available on the market, with validation often limited to testing relatively few clinical samples [15] , and some commercial ELISA kits have been validated worldwide [16] and approved by health regulatory agencies. However, none of the currently available serological kits are fully nationalized in several countries, which makes the products more expensive, less accessible, and subject to availability fluctuation due to international demands and importation difficulties. This is particularly critical in Brazil, considering that the country is the third in the world in number of cases, and the second in terms of death toll [1] . We aimed to developed a new ELISA kit to help COVID-19 diagnosis (henceforth named EIE COVID-19 IgG kit) through the detection of IgG antibodies against the SARS-CoV-2 nucleocapsid (N) protein. The full length coding region of the nucleocapsid (N) gene of SARS-CoV-2 (Genebank accession number: MT126808.1) was codon-optimized, subcloned into pET-24a-(+) expression vector and used to transform E.coli BL21(DE3) strain. Plasmid-positive clones were cultivated in LB medium, cultures were induced with IPTG (0,5 mM, 4h) and the recombinant protein expression levels were examined by SDS-PAGE. The recombinant antigen was purified by affinity chromatography using nickel columns in an AKTAprime plus system following manufacturer's instructions (GE Healthcare, USA). The use of sera samples from patients and healthy volunteers was approved by the UFMG's Ethics Committee and by the National Research Ethics' Committee (CAAE: 1686320.0.0000.5149). Negative sera obtained before 2020 are from healthy donors, and sera obtained after 2020 are from individuals who tested CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint were provided. Information on positive mildly symptomatic patients is available (Supplementary data Table S1 ). The median time between the PCR results and the first blood collection (out of serial collections) was 7 (± 1) days. In all, 894 samples were tested, 362 from SARS-CoV-2-positive patients (240 individuals), 407 from SARS-CoV-2-negative donors and 125 samples from patients bearing other different conditions (patients that were seropositive for other viruses, homolyzed sera, icteric sera and sera with increased levels of rheumatoid factors). Figure 1 summarizes how samples were used for the rN-ELISA kit validation. Experiments are categorized and showed in gray, positive samples (qPCR or DPP) in red, negative samples (negative PCR or pre-pandemic) in green and suspected cases (negative or no PCR data, but that had contact with confirmed COVID-19 individuals) in orange. The rN-ELISA sensitivity and specificity during internal validation included samples from healthy donors (n=81) and qPCR positive samples from hospitalized (n=11) and non-hospitalized individual (n=43). Agreement between rN-ELISA and DPP included: healthy donors tested by DPP (n=23), all qPCR+ samples (n=176) and suspected cases(n=62). The positive agreement to qPCR was calculated using samples from 43 non-hospitalized individuals (n= 157 samples, with information about the time after the qPCR confirmation). The ELISA was performed by coating plates of polystyrene (Costar, USA) with the recombinant antigen diluted in carbonate buffer to a final concentration of 4 μg/mL (overnight at 4 °C). Wells were blocked (PBS with 1% bovine serum albumin) for 2h at room temperature (25 ± 2°C). For each assay, samples . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint A cut-off value was determined using 88 samples from healthy donors (obtained before 2020) according to equation 1: : Average of negative samples (OD) : standard deviation of negative samples (OD) Positive and negative controls were prepared using heat-inactivated samples (56ºC, 30 minutes) [17] . The cut-off of the following tests was based on the positive control (equation 2): The internal evaluation of accuracy included the testing of 135 serum samples, from patients admitted to a hospital in Belo Horizonte (Minas Gerais, Brazil) and presenting positive PCR for COVID-19 (n=11); sera from non-hospitalized individuals (symptomatic or oligosymptomatic) presenting positive PCR for COVID-19 (n=43, 13±2,2 days post PCR confirmation); sera from healthy donors (taken after 2020) who tested negative for SARS-CoV-2 nasal swab PCR (n= 38); and sera from healthy donors who sampled blood before the COVID19 emergence (before 2020) (n=43). P values were determined through unpaired, two-sided Mann-Whitney U-test. To all validation assays, an index (I) for each sample was calculated, according to equation 3: The results were classified as: non-reactive (I<0.8), borderline (0.8≤ I <1.1) or reactive (I≥1.1). The full-length recombinant N protein (MW 48 KDa), was expressed at high yields in E. coli BL21(DE3) (60 mg of purified protein/mL of bacterial culture), and obtained at high purity grade (data not shown (Table 2) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint Forty-three individuals who tested positive for SARS-CoV-2 RNA through qRT-PCR were followed up for 30 days and assayed by the DPP rapid test and our rN-ELISA IgG kit. Of these, 19 presented a positive result for one or both serological test at the first blood collection and 24 patients were initially seronegative and then seroconverted during the follow up period. The median day of seroconversion for rN-ELISA IgG kit and DPP (IgG) was 14 days post PCR confirmation. All patients presented seroconversion as evaluated by the developed the rN-ELISA IgG kit within a maximum of 21 days after PCR confirmation (Supplementary materials, Table S4 ). The positive agreement to PCR was evaluated using 157 serum samples, collected at different timepoints. Considering borderline results as negative, the rN-ELISA IgG kit displayed a 48% (32/66) positive agreement to PCR before 10 days post molecular confirmation, 82% (54/66) from 11 to 20 days, and 100.0% (25/25) after 21 days. The DPP rapid test (serological reference method) displayed a 47% (31/66) positive agreement to PCR before 10 days post confirmation, from 11 to 20 days post-PCR confirmation, the positive agreement was 73% (48/66) and after 21 days, the positive agreement to PCR was 84% (21/25) ( Table 3) . cating a substantial agreement between both tests [18] . rN-ELISA IgG borderline results (n=19, three reactive by DPP and 16 non-reactive by DPP) were not included (Table 4) . Table 4 . Agreement between the rN-ELISA and DPP (serological reference) to detect IgG against SARS-CoV-2. Pos Total The rN-ELISA IgG kit was independently tested at three external laboratories: Laboratory of Virol- in all three studies (Table 5) . Serological tests, such as Enzyme-linked immunosorbent assay (ELISA) and rapid tests available in Brazil are dependent on imported technology. This is also true for many developing countries where the pandemic has hit hard. The main imported raw material is the antigen, which makes the diagnosis more expensive, less accessible and subject to availability fluctuation due to international demands. Here, we described the development of a serological assay to detect IgG antibodies against SARS-CoV-2 infection. For the production of the recombinant antigen, a crucial step in terms of performance and costs, we used a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint prokaryotic system because, in terms of scale production, bacteria-made proteins present cost-effective advantages when compared to eukaryotic systems, including higher productivity and reduced costs [19] . Most commercial COVID-19 serological assays available to date use the Spike protein as the antigen [8, [20] [21] [22] . However, to maintain its antigenic properties, this antigen must be produced in eukaryotic expression systems. The N protein has been described an immunodominant antigen generated during SASR-CoV-2 replication, and a superior antigenicity of N over S has been suggested [12, 23, 24] . Indeed, our rN-ELISA IgG kit based on the rN protein displayed similar performances when compared to tests from well-established manufacturers using the S1 antigen [25, 26] . In fact, we also produced different versions of the S1 fragment of the S antigen to be used as antigens in ELISA, in E. coli; however, the recombinant S1 proteins presented lower yields, insolubility, and poorer performances to recognize SARS-CoV-2-positive sera when compared to the N protein (data not shown). Even when we compared our rN protein with a S1 commercial antigen, produced in a eucaryotic system (HEK293 cells), using the same ELISA components, the performance of the test using the N protein to recognize anti-SARS-CoV-2 IgGs was superior (data not shown). Considering the easy production of the antigen, the robustness of the test, the technical familiarity and the wide use of ELISA in clinical laboratory settings, and the poor accessibility in developing regions to more robust techniques such as PCR, this product represents an important addition to the currently available serodiagnosis toolbox for diagnosis of COVID-19. Given that the developed rN-ELISA IgG kit presents high accuracy and robustness, it is amenable to be produced and can be considered as an excellent cost-benefit tool for detection of IgG antibodies in individual diagnosis or more broader applications, such as large-scale clinical studies and surveillance of SARS-CoV-2 infection. Supplementary Materials: Table S1 : Demographic and clinical variables of mild symptomatic patients with confirmed SARS-CoV-2 infection from the internal validation (n=43). Table S2 : Pre-pandemic samples used to calculate the cut-off during the rN-ELISA IgG internal validation. Table S3 : Samples from healthy donors used to calculate the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint rN-ELISA IgG specificity during the internal validation. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint Coronavirus COVID-19 Global Cases Faria, Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Performance of severe acute respiratory syndrome Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Serology and Early Investigation protocols Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1 Recombinant protein-based ELISA and immuno-cytochemical assay for the diagnosis of SARS Recombinant nucleocapsid protein-based IgG enzyme-linked immunosorbent assay for the serological diagnosis of SARS Relative rates of non-pneumonic sars coronavirus infection and SARS coronavirus pneumonia Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients A serological assay to detect SARS-CoV-2 seroconversion in humans Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region Evaluation of nine commercial SARS-CoV-2 immunoassays Food and Drug Administration) Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? Measuring agreement in method comparison studies Recombinant protein expression in Escherichia coli: Advances and challenges SARS-CoV-2 specific antibody responses in COVID-19 patients Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections Antibody responses to SARS-CoV-2 in patients with COVID-19 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity The authors declare no conflict of interest. Funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259392 doi: medRxiv preprint